Kornimate/medical-research-clean huggingface dataset:
the use of prophylactic antibiotics in the management of dog bites

Conditions: Bite; Wound; Infection

Summary: this double blinded rct will help to ascertain the usefulness of prophylactic antibiotics in the management of uncomplicated dog bites, utilizing currently best available antibiotics (augmentin) and an important clinical outcome of infection. by enrolling 100-150 patients in this pilot trial as part of a k-award the investigators plan to utilize the point estimates of infection, side effects and other important outcomes and incorporate these into a cost most to determine the most cost effective management of these wounds and to determine if further study is warranted based on the findings.

this double blinded rct will help to ascertain the usefulness of prophylactic antibiotics in the management of uncomplicated dog bites, utilizing currently best available antibiotics (augmentin) and an important clinical outcome of infection. by enrolling 100-150 patients in this pilot trial as part of a k-award the investigators plan to utilize the point estimates of infection, side effects and other important outcomes and incorporate these into a cost most to determine the most cost effective management of these wounds and to determine if further study is warranted based on the findings.

Eligibility criteria:
inclusion criteria: all patients including all children and english speaking/reading persons who present with a full thickness dog bite to participating emergency departments will be considered. non-english speaking/reading subjects for whom we can provide translation for will also be considered. exclusion criteria: exclusion criteria: * allergy to penicillin or amoxicillin/clavulanic acid * wounds presenting with an active infection (require antibiotics) or greater than 12 hours old. * patients with underlying fracture, joint or neurovascular injury, or multiple trauma requiring specialty referral. specifically any broken skin over a joint will need treatment and be excluded from the study and randomization. * patients on immunosuppressive agents, prolonged chronic steroid use (defined as continuous use for \> 14 days, 3 times a year) active hiv disease (determined by treating physician on history) or splenectomized. (could skew one group and at risk for overwhelming sepsis and death if infected) * patients unwilling or unable to complete the required follow-up, and those unable to provide a contact phone number

Keywords: dog bites infection prophylactic antibiotics cost effectiveness
effect of chondroitin sulphate on synovial inflammation in patients with osteoarthritis of the knee

Conditions: Synovitis; Osteoarthritis; Joint Diseases; Muskuloskeletal Diseases

Summary: the purpose of this study is to determine the effect of a chondroitin sulphate conventional treatment on the degree of severity of synovitis, as measured by magnetic resonance in patients with knee oa with clinical synovitis.


Eligibility criteria:
inclusion criteria: * primary oa of the knee according to acr with synovitis criteria (warmth, swelling or effusion); * oa of radiological stages 2 and 3 according to kellgren-lawrence; * minimum joint space width ≥2 mm in the medial femorotibial compartment on standing knee x-ray; * vas of pain while walking ≥40 mm. exclusion criteria: * known allergy to chondroitin sulphate; * progressive or serious pathologies (cancer, aids,...); * other bone and articular diseases (antecedents and/or current signs) such as chondrocalcinosis, paget's disease, rheumatoid arthritis, aseptic osteonecrosis, gout, septic arthritis, ochronosis, acromegaly, hemochromatosis, wilson's disease, osteochondromatosis; * corticosteroids (oral, injectable), indomethacin, therapeutic dose of glucosamine or chondroitin sulphate during the 12 weeks preceding inclusion; * hyaluronic acid (intra-articular pathway) during the 26 weeks preceding inclusion; * radioactive synovectomy during the 12 weeks preceding inclusion; * if the patient is receiving nsaid at baseline (d0), it should be maintained at a stable dosage as much as possible from d0 to d180. in the open phase of the study (d180 to d360), nsaid will also be allowed as rescue medication along with acetaminophen.

Keywords: chondroitin sulphate synovitis knee osteoarthritis magnetic resonance imaging
low-dose gated ct validity for the evaluation of ascendant aortic aneurysm.

Conditions: Ascendant Aortic Aneurysm

Summary: we will demonstrate the validity of measurements with a low-dose, ekg-gated ct without contrast in the ascending aorta evaluation, compared with the current angio-ct measurements.

the actual protocol used in aorta evaluation consist of two ct-scans on the same study. the first scan that detects calcifications is using parameters with low-dose current, non ekg-gated and without contrast. the second scan uses iodine-contrast, ekg-gating and higher current dose to obtain higher image quality of diagnostic value. the study will optimize the first scan parameters and compare the measures of the aorta diameters from the standard protocol. by modifying the first scan parameters, we would demonstrate that the follow-up of an aortic aneurysm can safely be made with lower radiation exposure.

Eligibility criteria:
inclusion criteria: * 60 years old and more * 85 bpm or less exclusion criteria: * aortic material * ekg gating not possible * aorta pathology (thrombus, dissection)
17 alfa hydroxyprogesterone caproate versus natural progesterone for the prevention of preterm labor

Conditions: Pregnancy

Summary: preterm deliveries play a significant role in neonatal morbidity and mortality. previous studies showed that administration of progesterone to pregnant women at high risk, decrease spontaneous preterm deliveries. the purpose of this study is to compare between two different modes of treatment with progesterone for the prevention of preterm delivery: weekly injection of 17 alfa hydroxyprogesterone caproate versus daily vaginal administration of progesterone in terms of efficacy, comfort and compliance, safety and cost of treatments.


Eligibility criteria:
inclusion criteria: * the subject has a history of spontaneous preterm delivery defined as earlier than 37 gestational week. * the subject has a short cervical length defined as 25 mm before 24 weeks gestation. * a singleton gestation. exclusion criteria: * multifetal pregnancy. * the subject has or will have a cervical cerclage in place.

Keywords: preterm delivery short cervical length progesterone
a study to evaluate the efficacy and safety of buma supreme drug eluting stent(des)

Conditions: Coronary Artery Disease

Summary: pioneer-ii rct trial is a prospective, multicenter, randomized, non-inferiority registry trial. 539 subjects from about 40 interventional cardiology centers in china will be enrolled to evaluate in-stent late lumen loss(lll) as the primary endpoint at 9 months. and all the subjects will be followed up to 5 years to attain the data of the secondary endpoints.

realizing even more uniform and complete endothelial coverage, buma supreme™ biodegradable drug coating coronary stent system comprises a new generation of biodegradable drug eluting stent under development by sinomed. buma supreme™ reconfigures buma™ des utilizing a high caliber cobalt chromium platform coated with rapidly degrading plga scaffold.

Eligibility criteria:
inclusion criteria: 1. age 18-75, male or non-pregnant female 2. evidence of non-symptomatic ischemia, stable or non-stable angina pectoris or past mi 3. target lesion is primary and de-novo coronary artery disease 4. the target lesion length ≤ 60 mm, diameter 2.25mm-5.0mm (visually estimated) 5. lesion diameter stenosis ≥70% (visually estimated) 6. for each target lesion, same stent implantation only 7. acceptable candidate for coronary artery bypass grafting (cabg) 8. understand the study purpose, willing to participate and sign the letter of consent, agrees to the follow-up visits including a 9 month angiographic follow-up exclusion criteria: 1. acute mi within 1 week 2. chronic total occlusion(timi 0), left main lesion, intervention-required three-vessel lesions, branch vessel diameter ≥ 2.5mm and bypass lesion 3. more than 3 stents required 4. patients refuse to be implanted stent 5. calcified lesion failed in pre-dilation, twisted lesion and lesion unsuitable for stent delivery and expansion 6. in-stent restenosis 7. planned percutaneous coronary intervention (pci) within 3 months post procedure 8. other stents implanted within 1 year 9. severe heart failure (nyha above iii) or left ventricle ejection fraction (ef) \<40% 10. renal function damage, blood creatinine \> 176.82 μmol/l 11. bleeding tendency, active peptic ulcer disease, cerebral or subarachnoid hemorrhage, cerebral apoplexy within half year and contraindication for any anti-platelet or anticoagulation agents 12. allergic to drugs or agents used in stent or protocol (plga, sirolimus, aspirin, clopidogrel, contrast agent, cobalt, nickel, chromium, iron, wolfram et. al.) 13. life expectation \< 12 months 14. have not reached the primary end point when participating in other trial 15. poor compliance to the protocol 16. heart implantation cases

Keywords: drug eluting stents interventional cardiology
effect of online education given to parent on motor social development for the premature babies in the neonatal intensive care unites

Conditions: Premature Infant

Summary: our study aim to evaluate the effect of online program that provides education to parents of premature infants in which stayed in the neonatal intensive care units (nicu),in their motor,socail-communişcation development and the parents stress level.

our study aim to increase the level f knowledge of the parents of premature infants that stayed in the nicu,to better manage their stress and to provide them with informations to support the motor and social-communication development of their infants.

Eligibility criteria:
inclusion criteria: * infants stayed in the neonatal intensive care unit for some time after premature birth for the purpose of care and treatment. * being a premature baby born at or under 32 weeks * infant corrected age between 0-8 months * to agree to participate in the study. exclusion criteria: * having a concomitant major anomaly and genetic disease * the fact that the family did not accept the evaluation of their baby in motor and social-communication area at sixth month of the study.

Keywords: premature infant,motor development,social-communication development,parental stress,online education
study comparing isolated pelvic perfusion with tnf-α 0.3 mg and melphalan 1.5 mg/kg versus standard treatment in patients with non resectable, recurrent gynaecologic or digestive pelvic cancer

Conditions: Gynaecologic or Digestive Pelvic Cancer

Summary: randomised phase 3 trial comparing 2 arms: an experimental treatment (isolated pelvis perfusion) and a standard treatment (systemic chemotherapy +/- radiotherapy +/- surgery). patients included have a non resectable, recurrent gynaecologic or digestive pelvic cancer. the aim of the study is to show a 25% increase in 1 year overall survival rate with isolated pelvic perfusion.


Eligibility criteria:
inclusion criteria: * histologically proved locally advanced gynaecologic or digestive tumours (epidermoid carcinomas, adenocarcinomas, neuroendocrine tumours, sarcomas or melanomas), (cervix, vagina, rectal, anal). * locally recurrent tumours for which surgical treatment will be mutilating or marginal (r1 or r2) and/or for cervix cancer, primary tumours non accessible for standard treatment (radiotherapy- chemotherapy - brachytherapy and surgery). * surgically resectable tumour (r0 type) but for which patient does not agree with surgery. * patients aged over 18 and under 76 ans * performance oms index ≤ 2 * normal biologic parameters * good general and cardiac state (asa i or ii and nyha i or ii) exclusion criteria: * surgically resectable tumour (ro) or peritoneal tumour extension or distant metastasis. * cardiac or vascular pathology * pulmonary disease * uncontrolled sepsis disease * pregnancy
capmatinib in patients with non-small cell lung cancer harboring cmet exon14 skipping mutation

Conditions: Cancer; Lung Cancer Metastatic; MET Gene Mutation

Summary: this study is a phase ii, single-arm, open label study under an umbrella trial for nsclc. this clinical study is targeted for the patients who harbor exon 14 skipping mutation of met and all patients will be treated with capmatinib. the treatment period begins on day 1 of cycle 1 and 1 cycle consists of 28 days.


Eligibility criteria:
inclusion criteria: * subjects with histologically or cytologically confirmed, unresectable stage iiib/iv nsclc that carries met exon 14 skipping alteration by molecular testing, as per ngs and rt pcr. * ecog performance status of 0 to 2 * male or female; ≥ 18 * subjects with measurable lesion (using recist 1.1 criteria) * subjects must have archival tissue sample available, collected either at the time of diagnosis of nsclc or any time since * patients who have progressed during or after 1st line or 2nd line therapy prior to the first dose of capmatinib. for patient who have received prior platinum containing adjuvant, neoadjuvant, or definitive chemoradiation for locally advanced disease, those treatments are regarded as 1st line if the progression has occurred \< 12 months from last therapy. exclusion criteria: * any major operation or irradiation within 4 weeks of baseline disease assessment * any clinically significant gastrointestinal abnormalities which may impair intake or absorption of the study drug * subjects with symptomatic central nervous system (cns) metastases who are neurologically unstable or have required increasing doses of steroids within the 2 weeks prior to study entry to manage cns symptoms * patients who have received more than 2 lines of prior systemic therapy, which include chemo, immune and targeted therapy
investigating the safety of post-surgical analgesics in children with obstructive sleep apnea

Conditions: Pediatric Obstructive Sleep Apnea Syndrome

Summary: every year thousands of young children with obstructive sleep apnea undergo surgery which requires them to be prescribed pain medication. the current standard in north america is administration of opioids, mainly codeine or morphine; however in many areas of the world including canada, nonsteroidal anti-inflammatory medications such as ibuprofen are used. some north american surgeons are uncertain regarding the potential of ibuprofen to increase bleeding following surgery. the results of research studies have been inconclusive overall. due to recent codeine fatalities in children following adenotonsillectomy, codeine has been removed from the formulary at many pediatric institutions. some surgeons have begun to use oral morphine as an alternate to codeine, which necessitates the need to find safe alternative analgesics in this treatment group. the primary objectives of this study is to assess the safety(1) and efficacy (2) of morphine and ibuprofen in children with sleep apnea. an interim analysis will be conducted after recruitment of 70 patients, to monitor both safety and efficacy


Eligibility criteria:
inclusion criteria: * diagnosed with osas, * scheduled for tonsillectomy plus/minus adenoid removal at mumc, * between the ages of 1-10years exclusion criteria: * contraindications to analgesia, * asthma, * has had previous adenotonsillectomy, or * any craniofacial, * neuromuscular or cardiac conditions

Keywords: pediatrics obstructive sleep apnea adenotonsillectomy analgesia
efficacy of hair transplantation compared with hypodermic needle irritation in alopecia areata

Conditions: Alopecia Areata; Alopecia; Balding

Summary: the purpose of this study is to look at the safety, as well as the efficacy of hair transplantation compared with irritation with hypodermic needles in the treatment of subjects with refractory alopecia areata. with this study, the investigators hope to demonstrate that trauma is just as effective as hair transplant in the treatment of recalcitrant alopecia areata of the scalp.

alopecia areata is a recurrent, non-scarring type of hair loss that can affect any hair-bearing area. this disorder can present in many different manners. though medically benign, alopecia areata can result in severe emotional and psychosocial stress in affected individuals. this disease can be treated by hair transplantation. hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. hairs generally continue to grow indefinitely during this study, subjects with alopecia areata will have one area (or ½ of a large area) treated by hair transplant and another (or the other ½) treated by simple irritation with a large gauge sterile hypodermic needle.

Eligibility criteria:
inclusion criteria: 1. subject must have recalcitrant, quiescent, alopecia areata, non-responsive to treatment, for at least 6 months. 2. subject must have one patch of alopecia areata greater than 5 cm diameter, of two patches of alopecia areata, each greater than 2.5 cm diameter. exclusion criteria: 1. subjects with active, progressive, alopecia areata. 2. subjects who are actively experiencing significant spontaneous regrowth of terminal hair. 3. subjects with autoimmune deficiency. 4. subjects with a medical condition contraindicating use of anesthesia.

Keywords: alopecia hair transplantation needle irritation medical needling
clinical impact of non-invasive neurally adjusted ventilatory assist in very preterm infants

Conditions: Preterm Infant

Summary: this is a prospective observational study investigating the impact of niv-nava on short-term clinical outcomes and long-term neurodevelopment in very preterm infants.


Eligibility criteria:
inclusion criteria: * preterm infants born between 27 weeks 0 days to 31 weeks 6 days of gestation * preterm infants who require respiratory support within the first 48 hours of life exclusion criteria: * preterm infants who die within the first 48 hours of life * preterm infants who do not require any respiratory support within the first 48 hours of life. * preterm infants with congenital anomalies affecting the lungs, heart, or other organs that could influence breathing * infants whose parents do not consent to participate in the study

Keywords: infant, premature noninvasive nava
vyxeos liposomal italian observational study in the real practice

Conditions: Acute Myeloid Leukemia (AML); Acute Myeloid Leukemia With Myelodysplasia-Related Changes; Therapy-Related Acute Myeloid Leukemia

Summary: the study is a prospective, single-arm, non-experimental, observational study in patients in italy with acute myeloid leukaemia (aml) with myelodysplastic-related changes or therapy related aml initiating treatment with jzp351 (vyxeos liposomal) in their normal clinical practice.


Eligibility criteria:
inclusion criteria: * patients newly diagnosed with aml-mrc (acute myeloid leukemia with myelodysplasia-related changes) or t-related aml (therapy related acute myeloid leukemia) following 2016 world health organization (who) classification. * age ≥ 18 years old. * patients considered eligible for intensive chemotherapy in the opinion of the treating physician. * patients who will initiate the treatment with commercially jzp351 treatment after the informed consent form (icf) signature. the decision to prescribe jzp351 treatment must have been made prior and regardless of the enrollment of the patient in the study. * cardiac ejection fraction ≥ 50% by echocardiography or muga (multi-gated acquisition). exclusion criteria: * prior treatment intended for induction therapy of aml (acute myeloid leukemia). * patients with prior cumulative anthracycline exposure of greater than 368 mg/m2 daunorubicin (or equivalent) * clinical evidence of active cns (central nervous system) leukemia. * patients with active (uncontrolled, metastatic) second malignancies.

Keywords: jzp351 cpx-351 vyxeos liposomal aml t-related aml aml-mrc
effect of motor imaginary training on upper limb functions in stroke

Conditions: Stroke, Cardiovascular

Summary: this study will provide knowledge about effectiveness of motor imaginary training in upper limb performance in chronic stroke patients. very little data is available about the use in motor imaginary in post stroke upper limb rehabilitation in pakistan. moreover, studies done previously did not specified population of stroke; this study will include mca stroke patients only, whom upper limb weakness is more prevalent.

motor imagery is a technique for inducing motor activity in response to a certain motor output by producing a mental image of the action without intending to conduct it. it is a cognitive technique that, rather than making a patient to pick up new procedures, promotes neural alterations in order enable the patient to re-acquire motor skills mastered before the cva or copy the actions of others. motor imaging training is a sort of therapy in which the patient imagines a gesture or movement in order to learn, reinforce, or improve the movement's performance. a study done in south korea, published in 2015, revealed that motor imagery training has a good impact on ul performance by refining functional mobility during stroke rehabilitation. the results suggest that motor imagery training is viable and helpful for improving ul function in cva patients. meta-analysis done in australia in the year 2013, was supportive of motor imaginary techniques further convincing that mental imagery can be a possible intervention for stroke patients given that it being, safe cost-effective \& unlimited practice opportunities. study done in china in 2017, suggested that clinicians should consider the use of mi in addition to treatment currently used to improve upper extremity functions after stroke as no evidence of side effects or harm was noted . rct done in year 2006 in usa indicated that for patients with chronic, moderate upper limb impairment after cva, program of cimt with mental practice only resulted in decrease impairment, with functional enhancement.

Eligibility criteria:
inclusion criteria: * mca stroke * chronic stroke patients * mini-mental state examination (mmse) score \>24 points * spasticity grade ii and iii on modified ashworth scale exclusion criteria: * severe cognitive disability such as depression, unilateral neglect, seizure, dementia, * any msk disorder including muscle contracture

Keywords: motor imaginary technique
effects of kinesio taping on balance and functional performance in stroke patients

Conditions: Stroke, Acute; Hemiplegia; Balance; Functional Performance

Summary: this study is planned to investigate the acute effects of trunk kinesio taping on balance and functional performance in acute stroke patients.


Eligibility criteria:
inclusion criteria: * 30-85 years * duration onset of stroke \< 1 month stroke time is between 0-1 months * score of modified rankin scale 0-3 * score of mini mental test ≥ 24 exclusion criteria: * not volunteering to participate in the study * having another stroke history * having a history of fracture or surgical operation involving the lower extremity * have another neurological or orthopedic disorder affecting functionality * having visual or hearing problems * presence of skin lesions (decubitus ulcer, active infection, burns, malignancy, cellulite, scar, etc.) at the site of application. * allergic reaction to kinesio tape * being obese

Keywords: acute stroke balance rehabilitation postural control